{"entity":{"id":"nct06008054","kind":"trial","name":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric ","aka":[],"tldr":"A phase 2 trial of Izalontamab brengitecan in colorectal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors is a phase 2 interventional study registered as NCT06008054 by Sichuan Baili Pharmaceutical Co., Ltd., with 376 participants planned, started 2023-11-16 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B003, BL-B01D1, PD-1 Monoclonal Antibody. Conditions listed: Esophageal Cancer, Gastric Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06008054","url":"https://clinicaltrials.gov/study/NCT06008054"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["adc","bispecific-adc"],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06008054","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06008054","source":"https://clinicaltrials.gov/study/NCT06008054","fetchedAt":"2026-10-07T16:54:05.353Z","studySha256":"6d3791e6a8ef7b3e0319cb09ddb1bae02f016fd800cf2369dc65c5adb1b435ad","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-26","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":376,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-11-16","startedType":"actual","enrolled":376,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06008054/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"drug":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}